AI-generated summary
The authors studied photothrombosis-induced stroke rats and a brain endothelial cell line, testing whether 808 nm photobiomodulation raises brain testosterone and improves vascular outcomes via androgen receptor signaling. They report that 7 days of treatment increased cerebrovascular testosterone, cerebral blood flow and vascular protein expression, reduced permeability and apoptosis, and improved behavior, with these effects reversed by the androgen receptor antagonist flutamide. The findings come from animal and cell experiments, so their relevance to humans is not established.
- Who or what was studied
- Photothrombosis-induced stroke rats and bEnd.3 brain endothelial cells subjected to oxygen-glucose deprivation
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The study used animal and cell-line models and the abstract does not report a human sample or clinical outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Methods
We measured behavioral performance, cerebral blood flow (CBF), vascular permeability, and the expression of vascular-associated and apoptotic proteins in PT-induced stroke rats treated with flutamide and seven consecutive days of PBM treatment (350 mW, 808 nM, 2 min/day). To gain further insights into the mechanism of PBM on testosterone synthesis, we used testosterone synthesis inhibitors to study their effects on bEND.3 cells.
Results
We showed that PT stroke caused a decrease in cerebrovascular testosterone concentration, which was significantly increased by 7-day PBMT (808 nm, 350 mW/cm2 , 42 J/cm2 ). Furthermore, PBMT significantly increased cerebral blood flow (CBF) and the expression of vascular-associated proteins, while inhibiting vascular permeability and reducing endothelial cell apoptosis. This ultimately mitigated behavioral deficits in PT stroke rats. Notably, treatment with the androgen receptor antagonist flutamide reversed the beneficial effects of PBMT. Cellular experiments confirmed that PBMT inhibited cell apoptosis and increased vascular-associated protein expression in brain endothelial cell line (bEnd.3) subjected to oxygen-glucose deprivation (OGD). However, these effects were inhibited by flutamide. Moreover, mechanistic studies revealed that PBMT-induced testosterone synthesis in bEnd.3 cells was partly mediated by 17β-hydroxysteroid dehydrogenase 5 (17β-HSD5).
Conclusions
Our study provides evidence that PBMT attenuates cerebrovascular injury and behavioral deficits associated with testosterone/AR following ischemic stroke. Our findings suggest that PBMT may be a promising alternative approach for managing cerebrovascular diseases.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nM, 808 nm
- Energy density (fluence)
- 42 J/cm2
- Power density (irradiance)
- 350 mW/cm2
- Power
- 350 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Stroke, Photobiomodulation, Cerebral blood flow. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.